Skip to main content
Menu

Posts tagged with "Business and Markets"

  • Business and Markets

    Piling On Andrew Witty

    To go along with the recent calls for Andrew Witty to step down at GSK, here’s John LaMattina wondering if he’s the right guy for the job as well: . . .the bigger issue with Witty’s stance is the direction that he is taking GSK. His company has a long and proud history of delivering… Read More
  • Alzheimer's Disease

    An Alzheimer’s IPO, Because Why Not

    Now here’s someone with optimism to burn, compost, and scatter to the winds. According to FierceBiotech, Vivek Ramaswamy has started a company called Axovant Pharmaceuticals, and their asset is a 5-HT6 antagonist from GSK. It goes back to the SmithKline days, when it was known as SB742457. It was in development for Alzheimer’s, apparent… Read More
  • Business and Markets

    Eli Lilly and Cambridge

    So Eli Lilly is opening a research center in Cambridge (specializing in drug delivery). This prompts several questions. Which big drug companies have not taken the Massachusetts Plunge, at least a little bit? (GSK and Roche don’t have much of a presence, to pick two). What finally made Lilly decide that they were missing out… Read More
  • Business and Markets

    A New Old Antibiotic

    Via FierceBiotech, here’s an odd story about a small company you’ve probably never hears of, Symbiomix. They were launched just a couple of years ago, and are now heading into Phase III with an antibiotic. How, you ask, is that remotely possible? Well, it’s an antibiotic (secnidazole, a nitroimidazole) that’s been sold in ot… Read More
  • Business and Markets

    Calls For Andrew Witty’s Job at GSK

    Here you are: a public call for the head of GlaxoSmithKline’s CEO, Andrew Witty: Witty, who’s led Britain’s largest drugmaker since 2008, is facing criticism for Glaxo’s lagging share performance and a depleted pipeline of promising medicines. A bribery scandal in China that led to a $489 million fine last year and sluggish U.S. sales… Read More
  • Business and Markets

    Market Exclusivity Is Sometimes Too Much

    Readers might remember a small company called Catalyst Pharmaceuticals, who have had a business plan that goes something like this: take the known small molecule that’s used for the rare disease Lambert-Eaton Myasthenic Syndrome LEMS, 3,4-diaminopyridine. Rebrand it as “Firdapse”, and do the clinical work needed to get it official… Read More
  • Business and Markets

    Looking Back At Merck/Schering-Plough

    Here’s Ed Silverman Peter Loftus at Pharmalot, looking back at the Merck/Schering-Plough merger. It has not gone quite like the initial plan: First, a little history. In November 2008, Schering-Plough Chief Executive Fred Hassan told analysts and investors gathered at the company’s Kenilworth, N.J., headquarters it was developing “five st… Read More
  • Business and Markets

    China’s First Homegrown Pharma

    The Wall Street Journal had an article on a new HDAC inhibitor from Shenzhen Chipscreen (full text here from The Australian). It’s worth highlighting. Epidaza (chidamide) appears to be the first homegrown drug discovery and development effort to reach regulatory approval in China. Their founder, Xian-Ping Lu, was working at Galderma before he… Read More
  • Academia (vs. Industry)

    Advice for Academic Entrepreneurs

    Since I’ve mentioned a recent book on academic drug discovery, I also wanted to highlight this article at Nature Biotechnology on university tech transfer offices (TTOs). The authors, mostly from a list of high-profile research universities (Oxford, Stanford, UCSF, University College London, Harvard et al.) and part of the Oxbridge Biotech Ro… Read More
  • Biological News

    A Couple of Ycombinator’s Startups

    Last year I mentioned reports that the startup incubator Ycombinator was thinking of getting into the biopharma field. Here’s a look at the current crop of potential companies. One thing that stands out is that most of these seem to be focused on patient care or some sort of diagnostic. One exception is 20n, which… Read More
...202122...